The green synthesis of a reduced graphene oxide (rGO) silica (SiO.sub.2) nanocomposite using Nigella sativa seed extract includes mixing a quantity of carbon source in an acid solution while stirring to obtain a solution; adding a first oxidant gradually into said solution to oxidize the soot and obtain a first suspension; stirring the first suspension while maintaining a temperature of said suspension to about 35° C.; adding plant seeds extract to the first suspension while raising the temperature of the suspension to about 60° C.; adding a second oxidant to said suspension to form the reduced graphene oxide nanoparticles; isolating the reduced graphene oxide nanoparticles by centrifugation; suspending the reduced graphene oxide nanoparticles in water; adding a solution comprising tetraethyl orthosilicate (TEOS), concentrated aqueous ammonia solution and a plant seeds extract under ultrasonication; and increasing the temperature to about 90° C. to form reduced graphene oxide-silicon dioxide nanocomposite suspension.

The green synthesis of a reduced graphene oxide (rGO) silica (SiO.sub.2) nanocomposite using Nigella sativa seed extract includes mixing a quantity of carbon source in an acid solution while stirring to obtain a solution; adding a first oxidant gradually into said solution to oxidize the soot and obtain a first suspension; stirring the first suspension while maintaining a temperature of said suspension to about 35° C.; adding plant seeds extract to the first suspension while raising the temperature of the suspension to about 60° C.; adding a second oxidant to said suspension to form the reduced graphene oxide nanoparticles; isolating the reduced graphene oxide nanoparticles by centrifugation; suspending the reduced graphene oxide nanoparticles in water; adding a solution comprising tetraethyl orthosilicate (TEOS), concentrated aqueous ammonia solution and a plant seeds extract under ultrasonication; and increasing the temperature to about 90° C. to form reduced graphene oxide-silicon dioxide nanocomposite suspension.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present invention relates to a novel use of sesquiterpenoid compounds, the pharmaceutically acceptable salts thereof, or the extracts of Cyperus rotundus comprising same or the fractions thereof in the prevention or treatment of menopausal diseases. The sesquiterpenoid compound according to the present invention, the extracts of Cyperus rotundus comprising the same or fractions thereof exhibit excellent estrogenic activity or anti-allergic activity, and therefore they can be used for the prevention or treatment of menopausal diseases caused by a decline in estrogen level or by allergic diseases.

The present invention relates to a novel use of sesquiterpenoid compounds, the pharmaceutically acceptable salts thereof, or the extracts of Cyperus rotundus comprising same or the fractions thereof in the prevention or treatment of menopausal diseases. The sesquiterpenoid compound according to the present invention, the extracts of Cyperus rotundus comprising the same or fractions thereof exhibit excellent estrogenic activity or anti-allergic activity, and therefore they can be used for the prevention or treatment of menopausal diseases caused by a decline in estrogen level or by allergic diseases.

Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

Novel plant products customized to provide a desired, consistent and stable Entourage of Interest (EOI) and processes for making and using the same are provided.

The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.

The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.

The embodiments use an innovative approach with the goal of permanent eradication of the virus. Instead of using drugs that block different stages of the virus life cycle (which have failed to induce a permanent cure), or approaches attempting to track infected cells, the embodiments use small virucidal molecules that are known to destroy the virus in vitro and that can easily penetrate all human cells, including memory cells or other reservoir cells. The problem with the use of small molecules is their toxicity to humans or animals when administered in doses sufficient to achieve intracellular concentrations high enough to destroy the virus in all forms. The embodiments overcome these toxicities (especially the comatose state) by using a 24-hour treatment with general anesthesia, endotracheal intubation with hemodynamic support, and controlled monitored ventilation; also, a combination of these molecules are used which decreases toxicity but has additive virucidal effects.